HSBC/CALL/MODERNA/280/0.1/20.06.24 Share Price

Warrant

DE000HG4AK66

Real-time BOERSE MUENCHEN 11:06:06 06/06/2024 pm IST
0.016 EUR 0.00% Intraday chart for HSBC/CALL/MODERNA/280/0.1/20.06.24
Date Price Change
06/24/06 0.016 0.00%
05/24/05 0.016 0.00%
04/24/04 0.016 0.00%
03/24/03 0.016 0.00%
31/24/31 0.016 0.00%

Real-time BOERSE MUENCHEN

Last update June 06, 2024 at 11:06 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying MODERNA, INC.
Issuer HSBC
WKN HG4AK6
ISINDE000HG4AK66
Date issued 23/06/2022
Strike 280 $
Maturity 20/06/2024 (14 Days)
Parity 10 : 1
Emission price 1.81
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 4.73
Lowest since issue 0.016
Delta0.01x
Omega 14.03
Premium78.71x
Gearing1692.89x
Moneyness 0.5598
Difference Strike 123.7 $
Difference Strike %+44.18%
Spread 0.015
Spread %93.75%
Theoretical value 0.008500
Implied Volatility 117.88 %
Total Loss Probability 99.57 %
Intrinsic value 0.000000
Present value 0.008500
Break even 280.09 €
Theta-0.01x
Vega0x
Rho0x

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
More about the company

Ratings for Moderna, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Moderna, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
154.8 USD
Average target price
142.8 USD
Spread / Average Target
-7.77%
Consensus